Statement: Heart-related adverse events were recorded in the secondary trial, but not  the primary trial.
Primary_evidence: Adverse Events 1:   Total: 5/32 (15.63%)   Febrile neutropenia 1/32 (3.13%)   Supraventricular tachycardia 1/32 (3.13%)   Hypersensitivity 2/32 (6.25%)   Catheter site infection 1/32 (3.13%)   Confusional state 1/32 (3.13%)
Secondary_evidence: Adverse Events 1:   Total: 285/752 (37.90%)   Anaemia 2/752 (0.27%)   Disseminated intravascular coagulation 2/752 (0.27%)   Febrile neutropenia 51/752 (6.78%)   Neutropenia 47/752 (6.25%)   Thrombocytopenia 2/752 (0.27%)   Atrial fibrillation 1/752 (0.13%)   Atrial flutter 0/752 (0.00%)   Cardiac failure congestive 1/752 (0.13%)   Left ventricular dysfunction 0/752 (0.00%) Adverse Events 2:   Total: 117/382 (30.63%)   Anaemia 3/382 (0.79%)   Disseminated intravascular coagulation 0/382 (0.00%)   Febrile neutropenia 11/382 (2.88%)   Neutropenia 20/382 (5.24%)   Thrombocytopenia 0/382 (0.00%)   Atrial fibrillation 1/382 (0.26%)   Atrial flutter 1/382 (0.26%)   Cardiac failure congestive 0/382 (0.00%)   Left ventricular dysfunction 1/382 (0.26%)